Source: Annual Congress 2003 - Alpha-1 antitrypsin deficiency and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Needham, D. M. Griffiths, H. M. Wilkins, R. A. Stockley (Birmingham, United Kingdom). Health status changes in alpha-1-antitrypsin deficiency (PiZ phenotype) over 3 years. Eur Respir J 2003; 22: Suppl. 45, 2481

Member's Comments

No comment yet.

Related content which might interest you: Health status changes in patients with alpha-1-antitrypsin deficiency Source: Eur Respir J 2002; 20: Suppl. 38, 249s Year: 2002 Mortality in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) Source: Eur Respir J 2006; 28: Suppl. 50, 144s Year: 2006 Risk of cancer in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) compared with the Swedish general population Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement? Year: 2020 Differences of disease phenotypes in individuals with alpha-1-antitrypsin deficiency with genotypes PiZZ and PiSZ - Analysis from the German registry Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Occupational exposure in alpha-1-antitrypsin deficiency (AATD) Source: Annual Congress 2008 - COPD and other environment-related lung diseases Year: 2008 Characterization of a population of alpha1-antitrypsin deficient (A1ATD) patients Source: Annual Congress 2008 - COPD Year: 2008 Prevalence of alpha-1-antitrypsin deficiency (A1AD) in patients with COPD. Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021 Health status measurements in alpha-1antitrypsin deficiency (AATD) Source: International Congress 2015 – Monitoring airway diseases with lung function tests Year: 2015 Frequency of α-1 antitrypsin deficiency (AATD) in a population screening in an high risk area (Val Trompia, Italy) Source: Eur Respir J 2006; 28: Suppl. 50, 453s Year: 2006 Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency Source: Annual Congress 2010 - COPD: phenotyping and monitoring Year: 2010 Tracing down the evolutionary history of Q0Ourém, a rare allele associated with severe alpha-1-antitrypsin deficiency (AATD) Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009 Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits Source: Eur Respir J, 50 (3) 1700198; 10.1183/13993003.00198-2017 Year: 2017 Severe alpha-1-antitrypsin deficiency (A1ATD) caused by Q0Ourém mutation: A clinical characterization Source: Annual Congress 2010 - Genetics of obstruction Year: 2010 Investigating change in the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD) Source: Annual Congress 2011 - Phenotyping and monitoring of airway diseases Year: 2011 Severity of lung disease in siblings with α-1-antitrypsin deficiency (AATD) Source: Annual Congress 2008 - COPD Year: 2008 Lung function at the age of 35 years in individuals with alpha-1-antitrypsin deficiency identified by neonatal screening Source: Annual Congress 2010 - The impact of genes and environment on obstructive airway diseases Year: 2010 Erythrocyte abnormalities in alpha-1-antitrypsin deficiency (AATD) patients Source: Annual Congress 2009 - COPD: exacerbation and clinical problems Year: 2009 Prevalence of alpha-1 antitrypsin deficiency (AATD) and frequencies of alleles PI*S and PI*Z in patients with COPD in Brazil Source: Annual Congress 2013 –Assessing the prevalence of COPD in the general population Year: 2013 Novel genetic variants in alpha-1 antitripsin deficiency cases carrying S alleles and discordant genotype and serum levels Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015